Ikuko Ota*, Yoshiaki Ota and Fuminori Taniguchi
The hormonal changes associated with menopause accounts for an unpleasant menopause symptom and a rapid decrease in bone mineral density. The former significantly impairs women's quality of life, and the latter causes locomotor disorders as well as osteoporosis in old age. Estrogen-Progestin Therapy (EPT) is useful for reducing menopausal symptoms (vasomotor symptoms (VMS) and vulvar/vaginal atrophy (VVA)) in postmenopausal women, and for preventing osteoporosis. However, EPT has the concerns about adverse effects on the breast, and endometrium such as Abnormal Uterine Bleeding (AUB). The Tissue Selective Estrogen Complex (TSEC) has improved safety and tolerability by combining the Selective Estrogen Receptor Modulators (SERMs), which have an estrogen agonist/antagonist effect on tissue selectivity, with estrogen. Bazedoxifene (BAZ), which has the strongest antagonistic effect on the breast and endometrium as SERM, was used in combination with the Conjugated Estrogen (CE). BAZ with CE has the effect of improving VMS and VVA, which is not found in a bazedoxifene monotherapy, and has prevented osteoporosis by normalizing bone metabolism. In addition, BAZ with CE it is safer for the endometrium and breast compared to EPT. It can be an option as a postmenopausal symptomatic Hormone Therapy (HT). In today's world of extended life expectancy, it is obviously meaningful for the old-aged women with postmenopausal symptoms to alleviate the necessity of the treatment for osteoporosis.
HTML PDFShare this article
